AUTHOR INDEX

(P = Proceedings, S = Supplement)

AASMUNDSTAD T.A., XU B.Q., JOHANNSSON I., RIPEL A., BJORNEBOE A., CHRISOPHERSEN A.S., BODD E. & MORLAND J. Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose, 611

ABDELMAWLA A.H., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Constriction of the dorsal hand vein to noradrenaline: comparison of cumulative and non-cumulative dose-response curves, 574P

ABDELMAWLA A.H., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Comparison of the effects of desipramine on noradrenaline- and methoxamine-evoked venoconstriction in man, 586P

ABDULLAH R. *see* DOCKRELL M.E.C.

ABERG J., EDGAR B., ERIKSSON P. & SWEDBERG K. Are the pharmacokinetics and haemodynamic effects of felodipine altered in patients with congestive heart failure, 573P

ADEBAYO G.I., GAFFNEY P. & FEELY J. A study of the temporal effect of alcohol on human erythrocyte sodium-lithium counter transport and membrane cholesterol/phospholipid, 584P

ADKIN D.A., DAVIS S.S., SPARROW R.A., HUCKEL P.D., PHILLIPS A.J. & WILDING I.R. The effects of pharmaceutical excipients on small intestinal transit, 381

ADRIAENS L. *see* KAMALI F.

AGRAWAL A., LAMB R.J., MERCER A.J. & POSNER J. The effects of lamotrigine (400 mg, 600 mg) and dipipanone (8 mg) on the cold pain test in healthy volunteers, 549P

AITCHISON K. *see* ARRANZ M.J.

AKERS W.S. *see* JOHNSON J.A.

ALARAYYED N.A., GRAHAM B.R., PRICHARD B.N.C. & SMITH C.C.T. The potentiation of adrenalin-induced *in vitro* platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects, 369

ALEXANDER J.M. *see* TRULL A.K.

ANDERSON P.J., CRITCHLEY J.A.J.H., TOMLINSON B. & RESPLANDY G. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers, 361

ANDERTON J.L. *see* RAPEPORT W.G.

ANSTEY K.J. *see* LORD S.R.

AOKI F.Y. *see* WONG L.T.Y.

APAYDIN S., TUNCOK Y., OTO O. & GUVEN H. Amikacin administration in open heart surgery, 578P

APSELOFF G.S., WILNER K.D. & GERBER N. Effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin in healthy volunteers, 29S

APSELOFF G.S., WILNER K.D., VON DEUTSCH D.A. & GERBER N. Tenidap sodium decreases renal clearance and increases steady-state concentrations of lithium in healthy volunteers, 25S

ARMAND P. *see* DURRIEU G.

ARONSON J.K. *see* BUCKLEY C.D.

AROSIO E. *see* MINUZ P.

ARRANZ M.J., DAWSON E., SHAIKH S., SHAM P., SHARMA T., AITCHISON K., CROCQ M.A., GILL M., KERWIN R. & COLLIER D.A. Cytochrome P4502D6 genotype does not determine response to clozapine, 417

ARVELA P. *see* SOTANIEMI E.A.

ASGHAR M.N. *see* FORD G.A.

ASHTON C.H. *see* TIFFIN P.A.

ATKINSON S. *see* HADIDI H.F.

BAAS H. *see* HARDER S.

BABER N. *see* HARRY J.D.

BACK D. *see* GIBB D.

BACK D.J. & McINNES G.T. Editorial comment: SI units—common sense not dogma is needed, 595

BACK D.J. *see* EALING V.A.

BACK D.J. *see* TJIA J.F.

BACK D.J. *see* VEAL G.A.

BACKSTROM M. *see* SOTANIEMI E.A.

BALDERSON D.J. *see* ROBERTS D.A.

BALL D.E., McLAUGHLIN W.S., SEYMOUR R.A. & KAMALI F. Effects of co-medication with enzyme-inducing drugs on the incidence of phenytoin-induced gingival overgrowth, 99P

BALL D.E., McLAUGHLIN W.S., SEYMOUR R.A. & KAMALI F. Plasma 5-(4-hydroxyphenyl)5-phenylhydantoin (HPPH) concentrations and resistance to phenytoin-induced gingival overgrowth in the rat, 568P

BALL D.E., McLAUGHLIN W.S., SEYMOUR R.A. & KAMALI F. Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in relation to gingival overgrowth in epileptic patients, 567P

BALL D.E., McLAUGHLIN W.S., SEYMOUR R.A. & KAMALI F. Potential inhibitors of phenytoin metabolism in the management of phenytoin-induced gingival overgrowth in the cat, 100P

BANSE H.H. *see* ULRICH S.

BAR P.R. *see* CONTERMANS J.

BARCLAY M.L. *see* BEGG E.J.

BARKWORTH M.F. *see* WALTER K.

BARONI S. *see* SCATENA R.

BARRETT P. *see* CRIBB A.E.

BARRY M. *see* GIBB D.

BARRY M. *see* VEAL G.A.

BATEMAN D.N. *see* CAMPBELL M.

BATEMAN D.N. *see* HARTIGAN-GO K.

BATTY K.T., DAVIS T.M.E., ILETT K.F., DUSCI L.J. & LANGTON S.R. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects, 305

BAYLIS E.M. *see* LAWSON G.K.

BEDDING A. *see* GUNPUT M.D.

BEGG E.J. & BARCLAY M.L. Aminoglycosides—50 years on, 597

BEGG E.J., BARCLAY M.L. & DUFFULL S.B. A suggested approach to once daily aminoglycoside dosing, 605

BELPAIRE F.M., WYNANT P., VAN TRAPPEN P., DHONT M., VERSTRAETE A. & BOGAERT M.G. Protein binding of propranolol and verapamil enantiomers in maternal and foetal serum, 190

BELTON K.J., LEWIS S.C., PAYNE S., RAWLINS M.D. & WOOD S.M. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom, 223

BENJAMIN N. *see* SZUMLANSKI C.L.

BENNETT P.N. *see* NOTARIANNI L.J.

BENNING B. *see* WOOD-BAKER R.

BENSON E. & WEBSTER J. The tolerability of amlodipine in hypertensive patients, 578P

BENVENUTI C. see ORLANDO R.

BERGEMANN N. *see* HARDER S.

BERGOUGNAN L. *see* STUBBS D.
BERLIN I. *see* DURRIEU G.
BERLIN I. *see* PATAT A.
BERLIN I., CHALON S., PAYAN C., SCHOLLNHAMMER G., CESSELIN F., VAROQUAUX O. & PUECH A.J. Evaluation of the α_2-adrenoceptor blocking properties of busipirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine, 243
BERNARD N. *see* FAUVEL J.P.
BERTILSSON L. *see* CHANG M.
BETSCHART B. *see* CENNI B.
BETTSCHEN H.-U. *see* WILDER-SMITH C.H.
BHAGAT K., COLLIER J. & VALLANCE P. Endogenous prostanoid-mediated venodilatation in humans, 543P
BIRD R. *see* DURSUN S.M.
BIRNIE D. *see* HOOD S.
BIRNIE D. *see* HOOD S.
BIRNIE D., HOGG K.J., GEMMILL J.D., CURZIO J., HOOD S., HOWIE K., RAE A.P., DUNN F.G. & HILLIS W.S. Greater coronary artery remodelling with a thromboxane A_2 receptor antagonist compared with warfarin, following successful thrombolysis, 95
BITSIOS P., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Modification of the mydriatic response to tyramine and methoxamine by clonidine, 575P
BJORNEBOE A. *see* AASMUNDSTAD T.A.
BLACKWELL C.P. *see* JOHNSON M.A.
BLIESATH H. *see* DUURSEMA L.
BLOCK G. *see* CUTLER N.
BLONDIN P. *see* STUBBS D.
BLUM R.A., SCHENTAG J.J., GARDNER M.J. & WILNER K.D. The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers, 35S
BODD E. *see* AASMUNDSTAD T.A.
BOGAERT M.G. *see* BELPAIRE F.M.
BOWES S.G. *see* CHARLETT A.
BOWES S.G. *see* KIROLLOS C.
BRADSHAW C.M. *see* ABDELMAWLA A.H.
BRADSHAW C.M. *see* BITSIOS P.
BRADSHAW C.M. *see* THEOFILOPOULOS N.
BRANDT R. *see* CENNI B.
BREEDVELD F.C. *see* VAN DEN BORNE B.E.E.M.
BREITENEDER H. *see* WOLTZ M.
BRITTEN A.J. *see* GHODSE H.
BRODIE M.J. *see* GREEN V.J.
BROHIER S. *see* ROSENZWEIG P.
BRONNER U., GUSTAFSSON L.L., DOUA F., ERICSSON O., MIEZAN T., RAIS M. & ROMBO L. Pharmacokinetics and adverse reaction after a single dose of pentamidine in patients with *Trypanosoma gambiense* sleeping sickness, 289
BROOM C. *see* FAIRLESS A.J.
BROSEN K. *see* MADSEN H.
BROSEN K. *see* RASMUSSEN B.B.
BROUARD R. *see* McINTYRE M.
BROWN-BONOMO J. *see* CRIBB A.E.
BRUGIER S. *see* VANDENBURG M.
BRUNING T.A., KEMME M.J.B., CHANG P.C., MUIZERT Y. & VAN ZWIETEN P.A. Calculation of plasma concentrations of intra-arterially infused compounds in forearm plethysmography: a novel approach, 540P
BRUNNER H.R. *see* MCINTYRE M.
BUCKLEY C.D. & ARONSON J.K. Prolonged half-life of verapamil in a case of overdose: implications for therapy, 680
BURGGRAAF J. *see* VISSER W.H.
BURNS N.J.T. *see* LI KAM WA T.C.
BUSS D.C. *see* WILLIAMSON I.J.
BYGATE E.A. *see* FAIRLESS A.J.

CAILLE Ph. *see* DURRIEU G.
CALDWELL J.R.S., KIRBY D.S., GARDNER M.J. & HANSEN R.A. The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis, 3S
CAMI J. *see* FARRE M.
CAMPBELL M. *see* THOMAS S.H.L.
CAMPBELL M., BATEMAN D.N. & SMITH J.M. Uptake of new drugs in hospitals in the Northern Region, 99P
CAMPBELL M., HOLDEN K., BATEMAN D.N. & SMITH J.M. Primary care prescribing of xamoterol in the northern region, 107P
CAMPEDELLI A. *see* MINUZ P.
CARROLL K. *see* DONOVAN A.J.G.
CARROLL K. *see* PEARS J.S.
CASTAGNOLA M. *see* SCATENA R.
CENNI B., MEYER J., BRANDT R. & BETSCHART B. The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum, 519
CERIMELE B. *see* REED S.
CERQUEIRA LOPES M.A. *see* SOARES R.
CESSELIN F. *see* BERLIN I.
CHADWICK I.G. *see* KRASKIEWICZ M.
CHADWICK I.G. *see* TODD G.P.
CHAKRABORTY J. *see* LAWSON G.K.
CHALLENOR J. *see* LINES C.
CHALON S. *see* BERLIN I.
CHALON S. *see* POUSSET F.
CHANG M., TYBRING G., DAHL M.-L., GOTHARSON E., SAGAR M., SEENSALU R. & BERTILSSON L. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19, 511
CHANG P.C. *see* BRUNING T.A.
CHARLETT A. *see* KIROLLOS C.
CHARLETT A., DOBBS R.J., O'NEILL C.J.A., PURKISS A.G., KIROLLOS C., BOWES S.G., WELLER C. & DOBBS S.M. Objective evaluation, using gait analysis, of potentially therapeutic interventions in elderly untreated sufferers from idiopathic parkinsonism, 569P
CHARLON V., DOLLOW. S., FIDEL J., HOGLUND C., HONKANEN T., KOBRIN I., McEWAN J., McINNES G., VISKOPER J.R. & SANG WOO K. Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study, 125
CHEN J. *see* HA H.R.
CHEYMOL G., WEISSENBURGER J., POIRIER J.M. & GELLEE C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects, 684
CHIBA K. *see* SETIABUDY T.
CHIBA K. *see* YOSHIMOTO K.
CHOLERTON S. *see* HADIDI H.F.
CHRISOPHERSEN A.S. *see* AASMUNDSTAD T.A.
CHRYSTYN H. *see* CORLETT S.A.
CLAPPERTON M., McMURRAY J., FISHER A.C. & DARGIE H.J. Does luminol chemiluminescence detect free radical scavengers? 688
CLAYDON P.J., DAVIES J.G. & COUTTS J. Glutamine clearance in critically ill patients receiving continuous venovenous haemofiltration, 588P
CLOUGH W. *see* STUBBS D.
COATES P.E.S. & MESURE R. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive, 47S
COATES P.E.S. & MESURE R. Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers, 17S
COATES P.E. *see* DEWLAND P.M.
COHEN A.F. *see* HUSSEIN Z.
COHEN A.F. *see* VISSER W.H.
COLLIER D.A. *see* ARRANZ M.J.
COLLIER J. *see* BHAGAT K.
COMERFORD M.B. *see* NYBERG G.F.
CONTERMANS J., SMIT J.W.A., BAR P.R. & ERKELENS D.W. A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients, 135

COOMBES J.A., GRAHAM P. & HARTLEY J.P.R. Inhibition of pentamidine-induced bronchoconstriction, 587P
COPE L.H. *see* KAMALI F.
CORFIELD J.E. *see* NASSIM M.A.
CORLETT S.A., PARKER D. & CHRYSTYN H. Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma, 452
COUTTS J. *see* CLAYDON P.J.
CRIBB A.E., TSUI B., ISBRUCKER R., MICHAEL R.T., GILLESPIE C.T., BROWN-BONOMO J., BARRETT P., LEVATTE T. & RENTON K.W. Assessment of arylamine *N*-acetyl transferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients, 85
CRITCHLEY J.A.J.H. *see* ANDERSON P.J.
CROCQ M.A. *see* ARRANZ M.J.
CURZIO J. *see* BIRNIE D.
CUTLER N., SRAMEK J., VEROFF A., BLOCK G., STAUFFER L. & LINES C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia, 333

DAHL M.-L. *see* CHANG M.
DALE-SMITH C.A. *see* LIU Z.
DALR-RE R. *see* GARCIA-LOSA M.
DARGIE H.J. *see* CLAPPERTON M.
DARIUS J., TROGER U. & MEYER P.P. Pharmacokinetics of VPA and ten of its metabolites: differences in homo- and heterozygotic twins, 560P
DARMANSJAH I. *see* SETIABUDY T.
DAVID G.K. *see* PIJL A.J.
DAVIE C.C. *see* ZUSSMAN B.D.
DAVIES J.G. *see* CLAYDON P.J.
DAVIS C.D., PIRMOHAMED M. & PARK B.K. Analysis of lymphocyte microsomal epoxide hydrolase activity in carbamazepine hypersensitive patients using [^{3}H]-cis-stilbene oxide, 554P
DAVIS S.S. *see* ADKIN D.A.
DAVIS T.M.E. *see* BATTY K.T.
DAWSON E. *see* ARRANZ M.J.
DE KONING P. & DE VRIES M.H. A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers, 7
DE LUNARDO C. *see* DRICI M.-D.
DE MEY C. Method specificity of the auscultatory estimates of the inodilatory reduction of diastolic blood pressure based on Korotkoff IV and V criteria, 485
DE SOLE P. *see* SCATENA R.
DE VOS J.W., UFKES J.G.R. & VAN WILGENBURG H. The role of methadone pharmacokinetics in managing maintenance therapy for opiate addicts is limited, 564P
DE VRIES M.H. *see* DE KONING P.
DE VRIES P.J. *see* WETSTEYN J.C.F.M.
DEAKIN J.W.F. *see* ROBERTS D.A.
DEGAN M. *see* MINUZ P.
DEL-PINO M. *see* MEGNIEN J.L.
DEMISCH L. *see* HARDER S.
DEWLAND P.M.S., GRIMWOOD V.C., RAPEPORT W.G. & COATES P.E. Effect of tenidap sodium on digoxin pharmacokinetics in healthy young men, 43S
DHONT M. *see* BELPAIRE F.M.
DIJKMANS B.A.C. *see* VAN DEN BORNE B.E.E.M.
DILDURANG STUDY GROUP *see* FRANCES Y.
DIQUET B. *see* POUSSET F.
DOBBS R.J. *see* CHARLETT A.
DOBBS R.J. *see* KIROLLOS C.
DOBBS S.M. *see* CHARLETT A.
DOBBS S.M. *see* KIROLLOS C.
DOBROCKY P. see NOTARIANNI L.J.
DOCHERTY A. *see* HOOD S.
DOCKRELL M.E.C., ABDULLAH R., STARKEY I.R., FLAPAN A.D. & WILLIAMS B.C. Diurnal variation in ADP induced platelet function in stable angina pectoris: a cyclooxygenase-independent mechanism, 543P
DOLLOW. S. *see* CHARLON V.
DONOVAN A.J.G. *see* PEARS J.S.
DONOVAN A.J.G., WILLIAMS A.J., TUERSLEY M.D., CARROLL K., YATES R.A. & SWEENEY M. A method for non-invasive assessment of the haemodynamic responses to isoprenaline infusions using transthoracic electrical bioimpedance (TEB) in healthy volunteers, 583P
DOUA F. *see* BRONNER U.
DRICI M.-D., RAYBAUD F., DE LUNARDO C., IACONO P. & GUSTOVIC P. Influence of the behaviour pattern on the nocebo response of healthy volunteers, 204
DUFFULL S.B. *see* BEGG E.J.
DUNCAN C. *see* SZUMLANSKI C.L.
DUNCAN L. *see* MILLAR S.A.
DUNN F.G. *see* BIRNIE D.
DUPONT A.G. *see* HARTMANN C.
DURRIEU G. *see* PATAT A.
DURRIEU G., PATAT A., BERLIN I., ARMAND P., MOLINIER P., CAILLE Ph. & ROSENZWEIG P. Oral tyramine pressor effect after chronic treatment with befloxatone in healthy volunteers, 574P
DURSUN S.M., BIRD R. & REVELEY M.A. Differential effects of transdermal nicotine patch on the symptoms of Tourette's syndrome, 100P
DUSCI L.J. *see* BATTY K.T.
DUURSEMA L., MULLER F.O., SCHALL R., MIDDLE M.V., HUNDT H.K.L., GROENEWOUD G., STEINIJANS V.W. & BLIESATH H. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin, 700

EALING V.A. & BACK D.J. Characterisation of testosterone metabolism by CYP3A4 expressed in a human lymphoblastoid cell line, 553P
ECHIZEN H. *see* YOSHIMOTO K.
ECKLAND D.J.A. *see* ENTWISLE S.J.
EDGAR B. *see* ABERG J.
EDWARDS C. *see* KAMALI F.
EGGERS K. & POWER I. Letter to the Editors. Tramadol hydrochloride—not just another opioid agonist, 338
EHRINGER H. *see* WOLTZ M.
EICHLER H.-G. *see* WOLTZ M.
ELIASSON T. *see* NYBERG G.F.
EMANUEL M. *see* KAMALI F.
ENEROTH P. *see* MOVIN-OSSWLAD G.
ENTWISLE S.J., FOWLER P.A., THOMAS M., ECKLAND D.J.A., LETTIS S., YORK M. & FREEDMAN P.S. The effects of oral sumatriptan, a 5-HT$_1$ receptor agonist, on circulating ACTH and cortisol concentrations in man, 389
ERICSSON O. *see* BRONNER U.
ERIKSSON P. *see* ABERG J.
ERKELENS D.W. *see* CONTERMANS J.

FAIRLESS A.J., PRATT S.K., WRITER D.J., FOWLES S.E., LAROCHE J., BYGATE E.A. & BROOM C. Dose-proportional pharmacokinetics of peniciclovir following intravenous administration to healthy volunteers, 553P
FARR S.J. *see* KHATTAB M.A.
FARRE M., LAMAS X. & CAMI J. Sensation seeking amongst healthy volunteers participating in phase I clinical trials, 405
FAUVEL J.P., BERNARD N., LAVILLE M., POZET N., SASSARD J. & ZECH P.Y. Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency, 187
FEELY J. *see* ADEBAYO G.I.
FERCHER A.F. *see* WOLTZ M.
FERGUSON J.S. & LEEMING M.R.G. Lack of photosensitising potential of tenidap, a novel anti-rheumatic agent, 63S
FERRARI M.D. see VISSER W.H.
FIDEL J. *see* CHARLON V.
FISHER A.C. *see* CLAPPERTON M.

FLANAGAN R.J. SI units—common sense not dogma is needed, 589
FLAPAN A.D. *see* DOCKRELL M.E.C.
FLETCHER A. Quality-of-life measurements in the evaluation of treatment:proposed guidelines, 217
FOALE R.A. *see* NYBERG G.F.
FOGARI R., ZOPPI A., MALAMANI G.D., MARASI G., VANASIA A. & VILLA G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients, 471
FOLLATH F. *see* HA H.R.
FORD G.A. & ASGHAR M.N. Management of hypertension in the elderly: attitudes of general practitioner and hospital physicians, 465
FORD G.A. *see* THOMAS S.H.L.
FORD J.M. *see* ROBERTS C.J.C.
FORD J.M. *see* WOOD D.M.
FORSTER D. *see* WATKINS W.M.
FORSTER E.R. *see* PALMER J.L.
FOSTER G. *see* YEO W.W.
FOUDA H.G. *see* GARDNER M.J.S.
FOWLER P.A. *see* ENTWISLE S.J.
FOWLER P.A. *see* VISSER W.H.
FOWLES S.E. *see* FAIRLESS A.J.
FOWLES S.E. *see* ZUSSMAN B.D.
FRANCES Y., GAGEY S., STALLA-BOURDILLON A. & DILDURANG STUDY GROUP Twenty-four hour efficacy of two dose levels of a once daily sustained-release diltiazem formulation in stable angina: a placebo-controlled trial, 277
FRANKE T. *see* MARTENS J.
FREEDMAN P.S. *see* ENTWISLE S.J.
FREESTONE S. *see* LI KAM WA T.C.
FREIBURGHAUS A.U. *see* HA H.R.
FREITAG T. *see* ULRICH S.

GAFFNEY P. *see* ADEBAYO G.I.
GAGEY S. *see* FRANCES Y.
GARCIA-LOSA M., DALR-RE R. & GARCIA-MENDEZ E. Improving patient recruitment in clinical trials: lessons from one multicentre study in asthma, 211
GARCIA-MENDEZ E. *see* GARCIA-LOSA M.
GARDNER J.J. *see* NASSIM M.A.
GARDNER M.J.S, WILNER K.D., HANSEN R.A., FOUDA H.G. & McMAHON G.F. Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects, 11S
GARDNER M.J. *see* BLUM R.A.
GARDNER M.J. *see* CALDWELL J.R.
GARDNER M.J. *see* WILNER K.D.
GELLEE C. *see* CHEYMOL G.
GEMMILL J.D. *see* BIRNIE D.
GERBER N. *see* APSELOFF G.S.
GHODSE H., TAYLOR D.R.S., GREAVES J.L., BRITTEN A.J. & LYNCH D. The opiate addiction test: a clinical evaluation of a quick test for physical dependence on opiate drugs, 257
GIAQUINTO C. *see* GIBB D.
GIARDINA B. *see* SCATENA R.
GIBB D., BARRY M., ORMESHER S., NOKES L., SEEFRIED M., GIAQUINTO C. & BACK D. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection, 527
GILL M. *see* ARRANZ M.J.
GILLESPIE C.T. *see* CRIBB A.E.
GJESDAL K. *see* KLEMSDAL T.O.
GLADZIWA U., WAGNER S., SIEBERTH H.-G. & KLOTZ U. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency, 161
GOEI THE H.S. *see* VAN DEN BORNE B.E.E.M.
GOTHARSON E. *see* CHANG M.
GRAHAM B.R. *see* ALARAYYED N.A.
GRAHAM P. *see* COOMBES J.A.
GRATTAN T.J., MARSHALL A.E., HIGGINS K.S. & MORICE A.H. The effects of inhaled and oral dextromethorphan on citric acid induced cough in man, 261
GREAVES J.L. *see* GHODSE H.
GREEN V.J., PIRMOHAMED M., KITTERINGHAM N.R., BRODIE M.J. & PARK B.K. Glutathione-S-transferase μ genotype (GSTMI*0) in patients with carbamazepine hypersensitivity, 555P
GREEN V.J., PIRMOHAMED M., KITTERINGHAM N.R., KNAPP M.J. & PARK B.K. Glutathionine S-transferase μ genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis, 411
GREENE P. *see* REED S.
GRILAGE G. *see* RAPEPORT W.G.
GRIMWOOD V.C. *see* DEWLAND P.M.
GRIMWOOD V.C. *see* RAPEPORT W.G.
GROENEWOUD G. *see* DUURSEMA L.
GROVE A. & LIPWORTH B.J. Tolerance with β_2-adrenoceptor agonists: time for reappraisal, 109
GUNPUT M.D., SOHAIL S. & BEDDING A. Assessment of fat-delayed gastric emptying using applied potential tomography in healthy subjects, 585P
GUNPUT M.D., WILLIAMS P., YOGENDRAN L., KEENE O.N. & MACONOCHIE J.G. QTc, PR interval and heart rate variability in healthy volunteers: a review of 12 lead ECG data from clinical pharmacology studies, 577P
GUSTAFSSON L.L. *see* BRONNER U.
GUSTOVIC P. *see* DRICI M.-D.
GUVEN H. *see* APAYDIN S.

HA H.R., CHEN J., FREIBURGHAUS A.U. & FOLLATH F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450, 321
HADIDI H.F., CHOLERTON S., ATKINSON S., IRSHAID Y.M., RAWASHDEH N.M. & IDLE J.R. The *N*-oxidation of trimethylamine in a Jordanian population, 176
HALLIDAY R.C., JONES B.C., KITTERINGHAM N.R., SMITH D.A. & PARK B.K. Halofantrine is an inhibitor, but not a substrate, of the polymorphic cytochrome P450 2D6(CYP2D6), 556P
HAMANAKA Y. *see* UENO T.
HAMMARLUND-UDENAES M. *see* PERSSON K.
HAMMARLUND-UDENAES M. *see* MOVIN-OSSWALD G.
HAMUNEN K., OLKKOLA K.T. & MAUNUKSELA E.L. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children, 241
HANSEN R.A. *see* CALDWELL J.R.
HANSEN R.A. *see* GARDNER M.J.
HAQ I.U., YEO W.W., JACKSON P.R. & RAMSAY L.E. Diets, HMG Co-A reductase inhibitors and target cholesterol in hypercholesterol-aemic subjects, 544P
HARDER S., BAAS H., BERGEMANN N., DEMISCH L. & RIETBROCK S. Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation, 39
HARRY J.D., BABER N. & POSNER J. Letter to the Editors. HIV screening in healthy volunteers, 213
HARTIGAN-GO K., BATEMAN D.N. & THOMAS S.H.L. Inter- and intra-observer errors in the measurement of the QY interval and QT dispersion, 104P
HARTIGAN-GO K., BATEMAN D.N. & THOMAS S.H.L. The effects of respiration on QT interval and QT dispersion, 105P
HARTIGAN-GO K., THOMAS S.H.L. & BATEMAN D.N. QT interval and QT dispersion: comparison of measurements made from 12 channel and single channel recordings, 104P
HARTLEY J.P.R. *see* COOMBES J.A.
HARTMANN C., VERCRUYSSE I., METZ T., MASSART D.L. & DUPONT A.G. Influence of nicardipine on the pharmacokinetics of propranolol in the elderly, 540P
HAYNES W.G. *see* NOON J.P.
HAYNES W.G. *see* STRACHAN F.E.
HELD P. *see* McCLENNEN W.
HELSBY N.A. *see* WRIGHT J.D.

HENDRICKS Y. *see* VANDENBURG M.
HIGGINS K.S. *see* GRATTAN T.J.
HIGGINS K.S. *see* TODD G.P.
HIGGINS K.S. *see* YEO W.W.
HIGHAM P.D. *see* THOMAS S.H.L.
HILLIS W.S. *see* BIRNIE D.
HILLIS W.S. *see* HOOD S.
HJEMDAHL P. *see* NYBERG G.F.
HOBBIGER S. *see* HUSSEIN Z.
HOCH O.D. *see* PROPPE D.G.
HOGERZEIL H.V. Promoting rational prescribing: an international perspective, 1
HOGG K.J. *see* BIRNIE D.
HOGLUND C. *see* CHARLON V.
HOLDEN K. *see* CAMPBELL M.
HOLFORD N.H.G., WILLIAMS P.E.O., MUIRHEAD G.J., MITCHELL A. & YORK A. Population pharmacodynamics of romarzit, 313
HOLGATE S.T. *see* WOOD-BAKER R.
HOLMBERG B. *see* NYBERG G.F.
HONKANEN T. *see* CHARLON V.
HOOD S. *see* BIRNIE D.
HOOD S., BIRNIE D., DOCHERTY A., HOWIE K., HOWIE K., PELL A., MURDOCH D. & HILLIS W.S. Changes in systolic time intervals: a non-invasive marker for the haemodynamic effects of sumatriptan, 95P
HOOD S., BIRNIE D., DOCHERTY A., PELL A., MURDOCH D. & HILLIS W.S. The central haemodynamic effects of subcutaneous sumatriptan, 96P
HOOYMANS P.M. *see* SCHOLS-HENDRICKS M.W.G.
HORN E.-P. *see* STEINFATH M.
HORNESTAM B. *see* McCLENNEN W.
HOSIE J. *see* RAPEPORT W.G.
HOWIE K. *see* BIRNIE D.
HOWIE K. *see* HOOD S.
HUANG M.L. *see* KAMALI F.
HUCKEL P.D. *see* ADKIN D.A.
HUMMEL T. & KOBAL G. Tramadol hydrochloride—not just another opioid agonist, 338
HUNDT H.K.L. *see* DUURSEMA L.
HUNDT H.K.L. *see* MEYER B.H.
HUNT W.B. *see* KIROLLOS C.
HUSSEIN Z., LEES K.P., MUIR K.W., LUNNON M., HOBBIGER S., WEATHERLEY B., POSNER J., VAN ROOY J., YATES R.A. & COHEN A.F. Pharmacokinetics of 619C89, a novel compound, in stroke patients: population *vs* non-compartmental analysis, 562P

IACONO P. *see* DRICI M.-D.
IDLE J.R. *see* HADIDI H.F.
ILETT K.F. *see* BATTY K.T.
INSUASTY J. *see* MCINTYRE M.
IRSHAID Y.M. *see* HADIDI H.F.
IRVING A. *see* STUBBS D.
ISBRUCKER R. *see* CRIBB A.E.
ISHIZAKI T. *see* SETIABUDY T.
ISHIZAKI T. *see* YOSHIMOTO K.

JACKSON P.R. *see* HAQ I.U.
JACKSON P.R. *see* KRASKIEWICZ M.
JACKSON P.R. *see* TODD G.P.
JACKSON P.R. *see* YEO W.W.
JACKSON S.H.D. *see* PECK R.W.
JAGATHESAN R., LEWIS L.D. & MANT T.G.K. Letter to the Editors. A retrospective analysis of the prevalence of HIV seropositivity and its demographics in the normal healthy volunteer population of a Phase-I clinical drug study unit, 463
JAMES I. *see* RAPEPORT W.G.
JAMIESON N.V. *see* TRULL A.K.
JANKNEGT R. *see* SCHOLS-HENDRICKS M.W.G.
JOHANNSSON I. *see* AASMUNDSTAD T.A.
JOHNSON J.A. & AKERS W.S. Influence of metabolites on protein binding of verapamil enantiomers, 536
JOHNSON M.A., BLACKWELL C.P. & SMITH J. Antagonism of the effects of clonidine by the α_2-adrenoceptor antagonist, fluparoxan, 477
JOHNSTON G.D. *see* NUGENT A.G.
JOHNSTON G.D. *see* PASSMORE A.P.
JOHNSTON S. *see* THAM T.C.K.
JONES B.C. *see* HALLIDAY R.C.
JONSSON U.E. *see* McCLENNEN W.
JULIEN J. *see* VANDENBURG M.
JUNGBLUTH G. *see* ULRICH S.

KALSO E. Letter to the Editors. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children, 214
KAMALI F. *see* BALL D.E.
KAMALI F. *see* NICHOLSON E.
KAMALI F. *see* THOMAS S.H.L.
KAMALI F. *see* TIFFIN P.A.
KAMALI F. *see* WANG M.
KAMALI F. *see* WOOD P.
KAMALI F., ADRIAENS L., HUANG M.L. & EMANUEL M. The effect of co-trimoxazole on the relative bioavailability of loperamide after oral administration of loperamide-oxide, 101P
KAMALI F., ADRIAENS L., HUANG M.L. & EMANUEL M. The effect of concurrent adminitration of co-trimoxazole on loperamide pharmacokinetics, 557P
KAMALI F., EDWARDS C., COPE L.H. & WYNNE H. The influence of age, liver volume and plasma enantiomer concentrations upon warfarin dose requirements, 102P
KAPOOR A., LETTIS S. & LACEY L.F. A study to determine the pharmacokinetic interaction between GR122311X and aspirin, 106P
KARLBERG B.E. *see* ZIEDEN B.
KEENE O.N. *see* GUNPUT M.D.
KELLAWAY I.W. *see* KHATTAB M.A.
KEMME M.J.B. *see* BRUNING T.A.
KERWIN R. *see* ARRANZ M.J.
KHATTAB M.A., FARR S.J. & KELLAWAY I.W. Partitioning and efflux of flurbiprofen and its octyl ester from liposomes, 559P
KILMINSTER S.G., SUTTON J.A. & MOULD G. Anxiety paradigm in healthy volunteers, 571P
KILMINSTER S.K. *see* SUTTON J.A.
KIRBY D.S. *see* CALDWELL J.R.
KIRCH W. *see* SIEPMANN M.
KIROLLOS C. *see* CHARLETT A.
KIROLLOS C., CHARLETT A., PURKISS A.G., O'NEILL C.J.A., BOWES S.G., HUNT W.B., WELLER C., DOBBS S.M. & DOBBS R.J. Methodology for objective measurement of activation of rigidity: diagnostic, therapeutic and pathogenetic implications for idiopathic Parkinsonism, 563P
KITTERINGHAM N.R. *see* GREEN V.J.
KITTERINGHAM N.R. *see* HALLIDAY R.C.
KIVISTO K.T. *see* LEHTO P.
KLEINBLOESEM C. *see* SIEPMANN M.
KLEMSDAL T.O., GJESDAL K. & ZAHLSON K. Physical exercise increases plasma concentrations of nicotine during treatment with a nicotine patch, 677
KLOTZ U. *see* GLADZIWA U.
KNAPP M.J. *see* GREEN V.J.
KOBAL G. *see* HUMMEL T.
KOBRIN I. *see* CHARLON V.
KOCH K. *see* PIJL A.J.
KOKWARO G. *see* WATKINS W.M.
KOOLEN J.J. *see* PIJL A.J.
KOOPMANS P.P. *see* VAN DEN VEN A.J.A.M.
KORLIPARA K. *see* RAPEPORT W.G.
KORTEN J.J. *see* SCHOLS-HENDRICKS M.W.G.
KRAMER NIELSEN K. *see* MADSEN H.
KRASKIEWICZ M., CHADWICK I.G., YEO W.W., JACKSON P.R. & RAMSAY L.E. Offset of ACE inhibitor cough after stopping enalapril: changes in cough symptoms, capsaicin-induced cough and skin responses to bradykinin, 545P
KUMAR R. *see* ZUSSMAN B.D.
KUSAKA M. *see* SETIABUDY T.

LACEY L.F. *see* KAPOOR A.
LAM W.K. *see* WILLIAMSON I.J.
LAMAS X. *see* FARRE M.
LAMB R.J. *see* AGRAWAL A.
LAMB R.J., MERCER A.J. &

POSNER J. The effect of lamotrigine (300 mg) and dipipanone (4 and 8 mg), alone and in combination, on the cold-pain test in healthy volunteers, 565P
LANDEWE R.B.M. *see* VAN DEN BORNE B.E.E.M.
LANG U. *see* ZUSSMAN B.D.
LANGLEY R.W. *see* ABDELMAWLA A.H.
LANGLEY R.W. *see* BITSIOS P.
LANGTON S.R. *see* BATTY K.T.
LAROCHE J. *see* FAIRLESS A.J.
LAVILLE M. *see* FAUVEL J.P.
LAWSON G.K., CHAKRABORTY J., TREDGER J.M. & BAYLIS E.M. Methylprednisolone-hemisuccinate and its metabolites in serum, urine and bile from two patients with actue graft rejection, 176
LECHAT P. *see* POUSSET F.
LECHI A. *see* MINUZ P.
LEE D.R. *see* PECK R.W.
LEE M.R. *see* LI KAM WA T.C.
LEEMING M.R.G. *see* FERGUSON J.
LEES K.P. *see* HUSSEIN Z.
LEHTO P. & KIVISTO K.T. Effects of milk and food on the absorption of enoxacin, 194
LETTIS S. *see* ENTWISLE S.J.
LETTIS S. *see* KAPOOR A.
LEVATTE T. *see* CRIBB A.E.
LEVENSON J. *see* MEGNIEN J.L.
LEVY G. Letter to the Editors. Protein binding of warfarin, 211
LEWIS L.D. *see* JAGATHESAN R,
LEWIS S.C. *see* BELTON K.J.
LI KAM WA T.C., BURNS N.J.T., WILLIAMS B.C., FREESTONE S. & LEE M.R. Blood and urine 5-hydroxytryptophan and 5-hydroxytryptamine precursors in normal man, 327
LIDMAN K. *see* NYBERG G.F.
LINES C. *see* CUTLER N.
LINES C., CHALLENOR J. & TRAUB M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260, 235
LIPWORTH B.J. *see* GROVE A.
LIU Z., MORTIMER O., DALE-SMITH C.A., WOLF C.R. & RANE A. Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism, 77
LOFT S. *see* RASMUSSEN B.B.
LOHMAN J.J.H.M. *see* SCHOLS-HENDRICKS M.W.G.
LORD S.R., ANSTEY K.J., WILLIAMS P. & WARD J.A. Psychoactive medication use, sensori-motor function and falls in older women, 227
LUNNON M. *see* HUSSEIN Z.
LYKKESFELDT J. *see* RASMUSSEN B.B.
LYNCH D. *see* GHODSE H.

MACFADYEN R.J. *see* MCINTYRE M.
MACKAY E. *see* VANDENBURG M.
MACONOCHIE J.G. *see* GUNPUT M.D.
MADSEN H., KRAMER NIELSEN K. & BROSEN K. Identification metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms—a population study, 433
MAENPAA J. *see* RASMUSSEN B.B.
MAGUIRE D. *see* VANDENBURG M.
MAKELA P.M. *see* WOOD D.M.
MALAMANI G.D. *see* FOGARI R.
MAN C.Y., SHEEHAN R.C., SMITH J. & VENTRESCA G.P. Effects of α_1/α_2-adrenoceptor blockade on the sytemic activity of the long-acting β_2-adrenoceptor agonist salmeterol, 587P
MANT T.G.K. *see* JAGATHESAN R.
MARASI G. *see* FOGARI R.
MAREE J.S. *see* MEYER B.H.
MARSH K. *see* WATKINS W.M.
MARSHALL A.E. *see* GRATTAN T.J.
MARTENS J., MEYER F.P., TROGER U. & FRANKE T. Loratadine and pheniramine: a new GC-MS assay and pharmacokinetic data at high serum levels, 560P
MASSART D.L. *see* HARTMANN C.
MATTIE H. *see* VAN DEN BORNE B.E.E.M.
MATTILA M.J., VAINIO P. & VANKOSKI J. Fluconazole moderately increases midozolam effects on performance, 567P
MAUNUKSELA E.L. *see* HAMUNEN K.
MAZZO M. *see* ORLANDO R.
MBERU E.K. *see* WATKINS W.M.
McCLENNEN W., HORNESTAM B., JONSSON U.E. & HELD P. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered with acute myocardial infarction, 704
McDADE G. *see* THEOFILOPOULOS N.
McEWAN J. *see* CHARLON V.
McGRATH B.P. & WATTS R.W. The comparative efficacy of two formulations of felodipine ER tablets in mild to moderate hypertensive patients, 94P
McGURK C. *see* NUGENT A.G.
McGURK C., NUGENT A.G. & SILKE B. A source of systematic error in the Hawksley random zero sphygmomanometer, 580P
McINNES G. *see* CHARLON V.
McINNES G.T. *see* BACK D.J.
McINTYRE M., MACFADYEN R.J., MEREDITH P.A., BROUARD R. & REID J.L. Dose ranging study of the AT_1 antagonist irbesartan (SR 47436-186295) in salt deplete, normal man, 579P
McINTYRE M., MACFADYEN R.J., MEREDITH P.A., MENARD J., BRUNNER H.R., INSUASTY J. & REID J.L. Comparative blood pressure and hormonal profile of enalapril and the AT_1 antagonist, UP 269-6, in salt deplete, normal man, 541P
McLAUGHLIN W.S. *see* BALL D.E.
McLEAN A.J. *see* PROPPE D.G.
McMAHON G.F. *see* GARDNER M.J.
McMURRAY J. *see* CLAPPERTON M.
MECHIE G.L. *see* RAPEPORT W.G.
MEGNIEN J.L., LEVENSON J., DELPINO M. & SIMON A. Amlodipine induces a flow and pressure-independent vasoactive effect on the brachial artery in hypertension, 641
MENARD J. *see* MCINTYRE M.
MERCER A.J. *see* AGRAWAL A.
MERCER A.J. *see* LAMB R.J.
MERCER A.J. *see* ROLAN P.E.
MEREDITH P.A. *see* McINTYRE M.
MERKI H.S. *see* WILDER-SMITH C.H.
MERKUS F.W.H.M. *see* SCHOLS-HENDRICKS M.W.G.
MESSANA I. *see* SCATENA R.
MESURE R. *see* COATES P.E.
METZ T. *see* HARTMANN C.
MEYER B.H., SCHOLTZ H.E., SCHALL R., MULLER F.O., HUNDT H.K.L. & MAREE J.S. The effect of fasting on total serum bilirubin concentrations, 161
MEYER F.P. *see* MARTENS J.
MEYER F.P. *see* ULRICH S.
MEYER J. *see* CENNI B.
MEYER P.P. *see* DARIUS J.
MICHAEL R.T. *see* CRIBB A.E.
MIDDLE M.V. *see* DUURSEMA L.
MIEZAN T. *see* BRONNER U.
MILLAR S.A., DUNCAN L. & TIPLADY B. Ethanol-induced CNS depression and divided attention, 548P
MILLSON D.S. *see* PEARS J.S.
MINUZ P., PANCERA P., RIBUL M., PRIANTE F., DEGAN M., CAMPEDELLI A., AROSIO E. & LECHI A. Amlodipine and haemodynamic effects of cycoloxygenase inhibition, 45
MITCHELL A. *see* HOLFORD N.H.G.
MIZUNO A. *see* UEMATSU T.
MOLINIER P. *see* DURRIEU G.
MOLNAR V. *see* PERSSON K.
MONAGHAN J.C. *see* STOKES G.S.
MONIE R.D.H. *see* WILLIAMSON I.J.
MORICE A.H. *see* GRATTAN T.J.
MORLAND J. *see* AASMUNDSTAD T.A.
MORTIMER O. *see* LIU Z.
MOULD G. *see* KILMINSTER S.G.
MOVIN-OSSWALD G., HAMMARLUND-UDENAES M.,

VON BAHR C., ENEROTH P. & WALTON-BROWN K. Influence of the dosing interval on prolactin release after remoxipride, 503
MUIR K.W. *see* HUSSEIN Z.
MUIRHEAD G.J. *see* HOLFORD N.H.G.
MUIZERT Y. *see* BRUNING T.A.
MULLER A. *see* ULRICH S.
MULLER F.O. *see* DUURSEMA L.
MULLER F.O. *see* MEYER B.H.
MULLER L.M. *see* VISSER W.H.
MULLER M. *see* WALTER K.
MUNTJEWERFF N.D. *see* RAMAEKERS J.G.
MURDOCH D. *see* HOOD S.
MURPHY S.A. *see* WATKINS W.M.
MWANGI I. *see* WATKINS W.M.

NAGASHIMA S. *see* UEMATSU T.
NAKAMURA M. *see* UEMATSU T.
NASSIM M.A., GARDNER J.J., WILKINSON D., CORFIELD J.E., RUDOL L. & WYLD P.J. The short-acting P2T-purinoceptor antagonist, FPL 67085, reliably, reversibly and safely inhibits ADP-induced platelet aggregation *ex vivo* in man, 98P
NEUHOF S. *see* ULRICH S.
NEWTON C.J. *see* WATKINS W.M.
NICHOLSON E. & KAMALI F. A high performance liquid chromatography method for the determination of 3,4-diamino-pyridine in human plasma, 102P
NIEVIECKI A.V. *see* WALTER K.
NOCCA G. *see* SCATENA R.
NOKES L. *see* GIBB D.
NOON J.P., SHORE A.C., HAYNES W.G., WALKER B.R. & WEBB D.J. The effects of brachial artery infusion of N^G-monoethyl-L-arginine on microvascular blood flow in healthy volunteers, 92P
NOTARIANNI L.J., OLIVER S.E., DOBROCKY P., BENNETT P.N. & SILVERMAN B.W. Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity, 65
NUGENT A.G. *see* McGURK C.
NUGENT A.G., McGURK C., RUTHERFORD R. & JOHNSTON G.D. Intra-arterial glyceryl trinitrate does not appear to affect venous compliance, 576P
NUGENT A.G., McGURK C., RUTHERFORD R. & JOHNSTON G.D. Peripheral haemodynamic effects of 5-HT in type 2 diabetes, 576P
NYBERG G.F., ELIASSON T., COMERFORD M.B., FOALE R.A., HJEMDAHL P., LIDMAN K. & TORFGARD K. Is there sympathetic activation with 'nitrate-free' and 'nitrate-low' periods in pulsed chronic oral nitrate treatment of β-adrenoceptor blocker treated angina patients, 584P
NYBERG G.F., ELIASSON T., HOLMBERG B., FOALE R.A. & COMERFORD M.B. Exercise tolerance before and 1 h after intermittent nitroglycerin patch and controlled-release mononitrate treatment of angina pectoris, 542P

O'DEA E. *see* WANG M.
O'HANLON J.F. *see* RAMAEKERS J.G.
O'NEILL C.J.A. *see* CHARLETT A.
O'NEILL C.J.A. *see* KIROLLOS C.
OLIVER S.E. *see* NOTARIANNI L.J.
OLKKOLA K.T. *see* HAMUNEN K.
OLSSON A.G. *see* ZIEDEN B.
OLSSON P., TAYLOR S.J., SMITH J. & VENTRESCA G.P. Pharmacokinetics of lexipafant after single and repeat oral doses and in fasted/fed conditions, 561P
OOSTERHUIS B. *see* WETSTEYN J.C.F.M.
ORLANDO R., BENVENUTI C., MAZZO M. & PALATINI P. The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis, 445
ORMESHER S. *see* GIBB D.
OSHIMA A. *see* UEMATSU T.
OTO O. *see* APAYDIN S.
OWEN F. *see* ROBERTS D.A.

PALATINI P. *see* ORLANDO R.
PALMER J.L. & FORSTER E.R. Differentiation of emesis and nausea exposure-response curves in the ipecacuanha-induced model of emesis in man, 97P
PANCERA P. *see* MINUZ P.
PARK B.K. *see* DAVIS C.D.
PARK B.K. *see* GREEN V.J.
PARK B.K. *see* HALLIDAY R.C.
PARKER D. *see* CORLETT S.A.
PASSMORE A.P., JOHNSTON G.D. & SILKE B. Effects of tertatolol on renal and cardiovascular haemodynamics in elderly hypertensive patients, 572P
PATAT A. *see* DURRIEU G.
PATAT A. *see* STUBBS D.
PATAT A., PERAULT M.C., VANDEL B., ULLIAC N., ZIELENIUK I. & ROSENZWEIG P. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on pyschomotor performance and memory in healthy volunteers, 31
PATAT A., WAROT D., BERLIN I., DURRIEU G., ZIELENIUK I. & PUECH A. Effects of celoxatone on psychomotor performance and memory, 565P
PAYAN C. *see* BERLIN I.
PAYNE S. *see* BELTON K.J.
PEARS J.S., TUERSLEY M.D., CARROLL K., MILLSON D.S. & WILLIAMS A.J. The effect of the β_3-adrenoceptor agonist ZD2079 on the cardiac response to intravenous isoprenaline in healthy male volunteers, 581P
PEARS J.S., TUERSLEY M.D., SHEALE R., DONOVAN A.J.G., MILLSON D.S. & WILLIAMS A.J. The effect of β_3-adrenoceptor agonist ZD2079 on the chronotropic and inotropic response to exercise in healthy male volunteers, 582P
PECK R.W., WOOTTON R., LEE D.R., JACKSON S.H.D. & POSNER J. The bioavailability and disposition of 1-(β-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent, 143
PELKONEN J. *see* RASMUSSEN B.B.
PELKONEN O. *see* SOTANIEMI E.A.
PELL A. *see* HOOD S.
PERAULT M.C. *see* PATAT A.
PERSSON K., SJOSTROM S., SIGURDARDOTTIR I., MOLNAR V., HAMMARLUND-UDENAES M. & RANE A. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extendsive metabolisers and one poor metaboliser of dextromethorphan, 182
PHILLIPS A.J. *see* ADKIN D.A.
PIEK J.J. *see* PIJL A.J.
PIJL A.J., VAN WEZEL H.B., KOOLEN J.J., PIEK J.J., KOCH K., SWAAN A., DAVID G.K., VISSER C.A. & VAN ZWIETEN P.A. The negative inotropic and chronotropic effects of intravenous R 56865 during percutaneous transluminal coronary angioplasty, 531
PILLAI D.N. *see* STOKES G.S.
PIRMOHAMED M. *see* DAVIS C.D.
PIRMOHAMED M. *see* GREEN V.J.
POIRIER J.M. *see* CHEYMOL G.
POSNER J. *see* AGRAWAL A.
POSNER J. *see* HARRY J.D.
POSNER J. *see* HUSSEIN Z.
POSNER J. *see* LAMB R.J.
POSNER J. *see* PECK R.W.
POSNER J. *see* ROLAN P.E.
POULSEN H.E. *see* RASMUSSEN B.B.
POUSSET F., CHALON S., THOMARE P., DIQUET B. & LECHAT P. Evaluation of cardiac β_1-adrenoceptor sensitivity with dobutamine in healthy volunteers, 633
POWER I. *see* EGGERS K.
POZET N. *see* FAUVEL J.P.
PRATT S.K. *see* FAIRLESS A.J.
PRIANTE F. *see* MINUZ P.
PRICHARD B.N.C. *see* ALARAYYED N.A.
PROPPE D.G., HOCH O.D., McLEAN A.J. & VISSER K.E. Letter to the Editors. Influence of chronic ingestion of grapefruit juice on

steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function, 337
PUECH A. *see* PATAT A.
PUECH A.J. *see* BERLIN I.
PULLAN T. *see* VANDENBURG M.
PURKISS A.G. *see* CHARLETT A.
PURKISS A.G. *see* KIROLLOS C.

RAE A.P. *see* BIRNIE D.
RAIS M. *see* BRONNER U.
RAMAEKERS J.G., MUNTJEWERFF N.D. & O'HANLON J.F. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and acutal driving performance, 397
RAMSAY L.E. *see* HAQ I.U.
RAMSAY L.E. *see* KRASKIEWICZ M.
RAMSAY L.E. *see* TODD G.P.
RAMSAY L.E. *see* YEO W.W.
RANE A. *see* LIU Z.
RANE A. *see* PERSSON K.
RAPEPORT W.G., GRIMWOOD V.C., HOSIE J., SLOAN P.M., KORLIPARA K., SILVERT B.D., JAMES I., MECHIE G.L. & ANDERTON J.L. The effect of tenidap on the anti-hypertensive efficacy of ACE inhibitors in patients treated for mild to moderate hypertension, 57S
RAPEPORT W.G. *see* DEWLAND P.M.
RAPEPORT W.G., GRIMWOOD V.C., KORLIPARA K., GRILAGE G., JAMES I., ANDERTON J.L. & SELFRIDGE I. The effect of tenidap on the anti-hypertensive efficacy of thiazide diuretics in patients treated for mild to moderate hypertension, 51S
RASMUSSEN B.B., MAENPAA J., PELKONEN J., LOFT S., POULSEN H.E., LYKKESFELDT J. & BROSEN K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine, 151
RAUTIO A. *see* SOTANIEMI E.A.
RAWASHDEH N.M. *see* HADIDI H.F.
RAWLINS M.D. *see* BELTON K.J.
RAYBAUD F. *see* DRICI M.-D.
REED S., GREENE P., RYAN T., CERIMELE B., SCHWERTSCHLAG U., WEINBERGER M. & VOELKER J. The renin angiotensin aldosterone system and frusemide response in congestive heart failure, 51
REID J.L. *see* McINTYRE M.
RENTON K.W. *see* CRIBB A.E.
RESPLANDY G. *see* ANDERSON P.J.
REVELEY M.A. *see* DURSUN S.M.
RHEINBERGER A. *see* WOLTZ M.
RIBUL M. *see* MINUZ P.
RICHENS A. Obituary. Paul Turner, 341
RIETBROCK S. *see* HARDER S.
RIPEL A. *see* AASMUNDSTAD T.A.
ROBERTS C.J.C. *see* WOOD D.M.
ROBERTS C.J.C., FORD J.M. & TRUMAN C.A. Is therapeutic monitoring of THA useful in Alzheimer's disease, 566P
ROBERTS D.A., BALDERSON D.J., DEAKIN J.W.F. & OWEN F. The abundance of dopamine D_4 receptor mRNA in post-morten brains of schizophrenics and controls, 547P
ROEWER N. *see* STEINFATH M.
ROLAN P.E., MERCER A.J., WOOTTON R. & POSNER J. Pharmacokinetics and pharmcodynamics of tucaresol, an antisickling agent, in healthy volunteers, 375
ROMBO L. *see* BRONNER U.
ROSENZWEIG P. *see* DURRIEU G.
ROSENZWEIG P. *see* PATAT A.
ROSENZWEIG P., BROHIER S. & ZIPFEL A. The placebo effect in healthy volunteers: influence of experimental conditions on physiological parameters during phase 1 studies, 657
ROUTLEDGE P.A. *see* WILLIAMSON I.J.
RUDOL L. *see* NASSIM M.A.
RUSSELL L. *see* WANG M.
RUTHERFORD R. *see* NUGENT A.G.
RYAN T. *see* REED S.

SAGAR M. *see* CHANG M.
SALOMON A. *see* WOLTZ M.
SAMAN A *see* WANG M.
SANG WOO K. *see* CHARLON V.
SASSARD J. *see* FAUVEL J.P.
SCATENA R., NOCCA G., MESSANA I., DE SOLE P., BARONI S., ZUPPI C., CASTAGNOLA M. & GIARDINA B. Effects of gemfibrozil on the oxygen transport properties of erythrocytes, 25
SCHALL R. *see* DUURSEMA L.
SCHALL R. *see* MEYER B.H.
SCHENTAG J.J. *see* BLUM R.A.
SCHMETTERER L. *see* WOLTZ M.
SCHOEMAKER R. *see* VISSER W.H.
SCHOLLNHAMMER G. *see* BERLIN I.
SCHOLS-HENDRICKS M.W.G., LOHMAN J.J.H.M., JANKNEGT R., KORTEN J.J., MERKUS F.W.H.M. & HOOYMANS P.M. Absorption of clonazepam after intranasal and buccal administration, 445
SCHOLTZ H.E. *see* MEYER B.H.
SCHWERTSCHLAG U. *see* REED S.
SEEFRIED M. *see* GIBB D.
SEENSALU R. *see* CHANG M.
SELFRIDGE I. *see* RAPEPORT W.G.
SETIABUDY T., KUSAKA M., CHIBA K., DARMANSJAH I. & ISHIZAKI T. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population, 297
SEYMOUR R.A. *see* BALL D.E.
SHAIKH S. *see* ARRANZ M.J.
SHAM P. *see* ARRANZ M.J.
SHARMA T. *see* ARRANZ M.J.
SHEALE R. *see* PEARS J.S.
SHEEHAN R.C. *see* MAN C.Y.
SHORE A.C. *see* NOON J.P.
SIEBERTH H.-G. *see* GLADZIWA U.
SIEPMANN M., KLEINBLOESEM C. & KIRCH W. The interaction of the calcium antagonist Ro-5976 with digoxin, 491
SIGURDARDOTTIR I. *see* PERSSON K.
SILKE B. *see* McGURK C.
SILKE B. *see* PASSMORE A.P.
SILVERMAN B.W. *see* NOTARIANNI L.J.
SILVERT B.D. *see* RAPEPORT W.G.
SIMON A. *see* MEGNIEN J.L.
SITAR D.S. *see* WONG L.T.Y.
SJOSTROM S. *see* PERSSON K.
SLOAN P.M. *see* RAPEPORT W.G.
SMIT J.W.A. *see* CONTERMANS J.
SMITH C.C.T. *see* ALARAYYED N.A.
SMITH D.A. *see* HALLIDAY R.C.
SMITH J. *see* JOHNSON M.A.
SMITH J. *see* MAN C.Y.
SMITH J. *see* OLSSON P.
SMITH J. *see* VENTRESCA G.P.
SMITH J.M. *see* CAMPBELL M.
SMITH L. *see* SZUMLANSKI C.L.
SMITH R. *see* WOOD-BAKER R.
SOARES R. & CERQUEIRA LOPES M.A. Effects of captopril on the human foetal placental circulation: an interaction with bradykinin and angtiotensin, 497
SOHAIL S. *see* GUNPUT M.D.
SOTANIEMI E.A., RAUTIO A., BACKSTROM M., ARVELA P. & PELKONEN O. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and courmarin in patients with liver and kidney diseases and epileptic patients, 71
SOURGENS H. *see* ZUSSMAN B.D.
SPARROW R.A. *see* ADKIN D.A.
SRAMEK J. *see* CUTLER N.
STALLA-BOURDILLON A. *see* FRANCES Y.
STANISLAUS F. *see* WALTER K.
STARKEY I.R. *see* DOCKRELL M.E.C.
STAUFFER L. *see* CUTLER N.
STEINFATH M., HORN E.-P. & ROEWER N. Clonidine administered intraoperatively prevents postoperative shivering, 580P
STEINIJANS V.W. *see* DUURSEMA L.
STOKES G.S., MONAGHAN J.C. &

PILLAI D.N. Investigation of the roles of dopamine and prostaglandins in the natriuresis following an intravenous saline load, 92P
STOREY P. *see* STRACHAN F.E.
STRACHAN F.E., HAYNES W.G., STOREY P. & WEBB D.J. Endothelin type A and B receptors mediate venoconstriction in humans, 546P
STUBBS D., BLONDIN P., PATAT A., BERGOUGNAN L., IRVING A. & CLOUGH W. Lack of interaction between a new anti-histamine, mizolastine, and ethanol on psychomotor and driving performance in healthy volunteers, 570P
SUTTON J.A. & KILMINSTER S.K. Dose-related effect of octylonium bromide on colonic transport, but not proximal gut, in normal volunteers, 107P
SUTTON J.A. *see* KILMINSTER S.G.
SUZUKI T. *see* UENO T.
SWAAN A. *see* PIJL A.J.
SWEDBERG K. *see* ABERG J.
SWEENEY M. *see* DONOVAN A.J.G.
SZABADI E. *see* ABDELMAWLA A.H.
SZABADI E. *see* BITSIOS P.
SZABADI E. *see* THEOFILOPOULOS N.
SZUMLANSKI C.L., SMITH L., DUNCAN C. & BENJAMIN N. The effects of amoxycillin on salivary nitrite concentrations: an important mechanism of adverse reactions, 460

TAN K.K.C. *see* TRULL A.K.
TAN L. *see* TRULL A.K.
TANAKA A. *see* UENO T.
TANI M. *see* YOSHIMOTO K.
TAYLOR D.R.S. *see* GHODSE H.
TAYLOR S.J. *see* OLSSON P.
TAYLOR S.J. *see* VENTRESCA G.P.
THAM T.C.K., JOHNSTON S. & WATSON G.P. Patient knowledge and presciption of ulcer healing drugs in medical inpatients, 197
THEOFILOPOULOS N., McDADE G., SZABADI E. & BRADSHAW C.M. Effects of reboxetine and desipramine on the kinetics of the pupillary light reflex, 251
THOMARE P. *see* POUSSET F.
THOMAS M. *see* ENTWISLE S.J.
THOMAS S.H.L. & CAMPBELL M. Prescribing of appetite suppressants in England: an inverse marker prescribing quality? 97P
THOMAS S.H.L. *see* HARTIGAN-GO K.
THOMAS S.H.L. *see* WOOD P.
THOMAS S.H.L., HIGHAM P.D., KAMALI F. & FORD G.A. Concentration-dependent effects of terodiline enantiomers on the QT interval in asymptomatic patients on chronic therapy, 94P
TIFFIN P.A., ASHTON C.H. & KAMALI F. Caffeine pharmacokinetics and effects on psychomotor performance in poor and normal sleepers, 558P
TIPLADY B. *see* MILLAR S.A.
TJIA J.F. & BACK D.J. Theophylline *N*-demethylation and hydroxylation exhibit biphasic kinetics in human liver microsomes: inhibition studies, 552P
TODD G.P., CHADWICK I.G., HIGGINS K.S., YEO W.W., JACKSON P.R. & RAMSAY L.E. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects, 131
TOMLINSON B. *see* ANDERSON P.J.
TORFGARD K. *see* NYBERG G.F.
TOWN G.I. *see* WOOD-BAKER R.
TRAUB M. *see* LINES C.
TREDGER J.M. *see* LAWSON G.K.
TROGER U. *see* DARIUS J.
TROGER U. *see* MARTENS J.
TRULL A.K., TAN K.K.C., TAN L., ALEXANDER J.M. & JAMIESON N.V. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion, 627
TRUMAN C.A. *see* ROBERTS C.J.C.
TSUI B. *see* CRIBB A.E.
TUERSLEY M.D. *see* DONOVAN A.J.G.
TUERSLEY M.D. *see* PEARS J.S.
TUNCOK Y. *see* APAYDIN S.
TYBRING G. *see* CHANG M.

UEMATSU T., MIZUNO A., NAGASHIMA S., OSHIMA A. & NAKAMURA M. The axial distribution of nicotine content along hair shaft as an indicator of changes in smoking behaviour: evaluation in a smoking-cessation programme with or without the aid of nicotine chewing gum, 665
UENO T., TANAKA A., HAMANAKA Y. & SUZUKI T. Serum drug concentrations after oral administration of paracetamol to patients with surgical resection of the gastrointestinal tract, 330
UFKES J.G.R. *see* DE VOS J.W.
ULLIAC N. *see* PATAT A.
ULRICH S., MEYER F.P., NEUHOF S., BANSE H.H., FREITAG T., JUNGBLUTH G. & MULLER A. Investigation of oral and i.m. treatment of schizophrenics with flupenthixol, 570P
UNFRIED C. *see* WOLTZ M.

VAINIO P. *see* MATTILA M.J.
VALLANCE P. *see* BHAGAT K.
VAN BOXTEL C.J. *see* WETSTEYN J.C.F.M.
VAN DEN BIGGERLAAR-MARTEA M. *see* VREE T.B.
VAN DEN BORNE B.E.E.M., LANDEWE R.B.M., GOEI THE H.S., MATTIE H., BREEDVELD F.C. & DIJKMANS B.A.C. Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis, 172
VAN DEN VEN A.J.A.M., VREE T.B., VAN EWIJK-BENEKEN KOLMER E.W.J., KOOPMANS P.P. & VAN DER MEER J.W.M. Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole, 621
VAN DER MEER J.W.M. *see* VAN DEN VEN A.J.A.M.
VAN EWIJK-BENEKEN KOLMER E.W.J. *see* VAN DEN VEN A.J.A.M.
VAN ROOY J. *see* HUSSEIN Z.
VAN TRAPPEN P. *see* BELPAIRE F.M.
VAN WEZEL H.B. *see* PIJL A.J.
VAN WILGENBURG H. *see* DE VOS J.W.
VAN ZWIETEN P.A. *see* BRUNING T.A.
VAN ZWIETEN P.A. *see* PIJL A.J.
VANASIA A. *see* FOGARI R.
VANDEL B. *see* PATAT A.
VANDENBURG M., MACKAY E., PULLAN T., MAGUIRE D., HENDRICKS Y., BRUGIER S. & JULIEN J. An 8 week placebo-controlled dose titration study of imidapril in the treatment of mild to moderate essential hypertension, 93P
VANKOSKI J. *see* MATTILA M.J.
VAROQUAUX O. *see* BERLIN I.
VEAL G.A., BARRY M. & BACK D.J. *In vitro* phosphorylation of the dideoxynucleotide analogue zalcitabine, 551P
VENTRESCA G.P. *see* MAN C.Y.
VENTRESCA G.P. *see* OLSSON P.
VENTRESCA G.P., SMITH J. & TAYLOR S.J. The effects of oral lexipafant on *ex vivo* platelet aggregation and intradermal PAF challenge in healthy subjects, 546P
VERCRUYSSE I. *see* HARTMANN C.
VERE D.W. A Latin Square design to detect crossover effects in a clinical trial, 106P
VEROFF A. *see* CUTLER N.
VERSTRAETE A. *see* BELPAIRE F.M.
VERWEY-VAN WISSEN C.P.W.G.M. *see* VREE T.B.
VILLA G. *see* FOGARI R.
VISKOPER J.R. *see* CHARLON V.
VISSER C.A. *see* PIJL A.J.

VISSER K.E. *see* PROPPE D.G.
VISSER W.H., BURGGRAAF J., MULLER L.M., SCHOEMAKER R., FOWLER P.A., COHEN A.F. & FERRARI M.D. Pharmacokinetic differences between migraine patients with and without headache relief and between patients with and without headache recurrence after sumatriptan, 572P
VOELKER J. *see* REED S.
VON BAHR C. *see* MOVIN-OSSWALD G.
VON DEUTSCH D A. *see* APSELOFF G.
VREE T.B. *see* VAN DEN VEN A.J.A.M.
VREE T.B., VAN DEN BIGGERLAAR-MARTEA M. & VERWEY-VAN WISSEN C.P.W.G.M. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide, 692

WAGNER S. *see* GLADZIWA U.
WALKER B.R. *see* NOON J.P.
WALLEY T. Drugs, money and society, 343
WALTER K., MULLER M., BARKWORTH M.F., NIEVIECKI A.V. & STANISLAUS F. Pharmacokinetics of physostigmine in man following a single application of a transdermal system, 59
WALTON-BROWN K. *see* MOVIN-OSSWALD G.
WANG M., O'DEA E., RUSSELL L., SAMAN A. & KAMALI F. A double-blind comparison of patient-controlled analgesia *vs* continuous infusion with morphine for relief of post-operative pain, 549P
WARD J.A. *see* LORD S.R.
WARD S.A. *see* WRIGHT J.D.
WARGENAU M. *see* ZUSSMAN B.D.
WAROT D. *see* PATAT A.
WATKINS W.M., WINSTANLEY P.A., MBERU E.K., KOKWARO G., MURPHY S.A., NEWTON C.J., MWANGI I., FORSTER D. & MARSH K. Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria, 283
WATSON G.P. *see* THAM T.C.K.
WATTS R.W. *see* McGRATH B.P.
WEATHERLEY B. *see* HUSSEIN Z.
WEBB D.J. *see* NOON J.P.
WEBB D.J. *see* STRACHAN F.E.
WEBSTER J. *see* BENSON E.
WEINBERGER M. *see* REED S.
WEISSENBURGER J. *see* CHEYMOL G.
WELLER C. *see* CHARLETT A.
WELLER C. *see* KIROLLOS C.
WETSTEYN J.C.F.M., DE VRIES P.J., OOSTERHUIS B. & VAN BOXTEL C.J. The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis, 696
WILDER-SMITH C.H., BETTSCHEN H.-U. & MERKI H.S. Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH feedback-controlled and fixed-dose infusions, 15
WILDING I.R. *see* ADKIN D.A.
WILKINSON D. *see* NASSIM M.A.
WILLIAMS A.J. *see* DONOVAN A.J.G.
WILLIAMS A.J. *see* PEARS J.S.
WILLIAMS B.C. *see* DOCKRELL M.E.C.
WILLIAMS B.C. *see* LI KAM WA T.C.
WILLIAMS P. *see* GUNPUT M.D.
WILLIAMS P. *see* LORD S.R.
WILLIAMS P.E.O. *see* HOLFORD N.H.G.
WILLIAMSON I.J., YEW W.W., LAM W.K., MONIE R.D.H., BUSS D.C. & ROUTLEDGE P.A. Single sample acetylator phenotype test using isoniazid in a Chinese population, 551P
WILNER K.D.S. & GARDNER M.J. Cimetidine does not alter the clearance or plasma binding of tenidap in healthy male volunteers, 21S
WILNER K.D.S. & GARDNER M.J. Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers, 39S
WILNER K.D. *see* APSELOFF G.
WILNER K.D. *see* BLUM R.A.
WILNER K.D. *see* GARDNER M.J.
WINSTANLEY P.A. *see* WATKINS W.M.
WOLF C.R. *see* LIU Z.
WOLTZ M., SCHMETTERER L., RHEINBERGER A., SALOMON A., UNFRIED C., BREITENEDER H., EHRINGER H., EICHLER H.-G. & FERCHER A.F. Comparison of non-invasive methods for the assessment of haemodynamic drug effects in healthy male and female volunteers: sex differences in cardiovascular responsiveness, 347
WONG L.T.Y., SITAR D.S. & AOKI F.Y. Chronic tobacco smoking and gender as variables affecting amantidine disposition in healthy subjects, 81
WOOD D.M., FORD J.M., MAKELA P.M. & ROBERTS C.J.C. The characterisation of the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride), 556P
WOOD D.M., MAKELA P.M., FORD J.M. & ROBERTS C.J.C. Is the plasma protein binding of tacrine hydrochloride (THA) affected by its major metabolite (1-hydroxy THA)? 103P
WOOD P., THOMAS S.H.L. & KAMALI F. Measurement of the (R)- and (S)-enantiomers of terodiline in human plasma by chiral high performance liquid chromatography, 558P
WOOD R. Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisonopril. A controlled retrospective cohort study, 265
WOOD S.M. *see* BELTON K.J.
WOOD-BAKER R., SMITH R. & HOLGATE S.T. A double-blind, placebo controlled study of the effect of the specific histamine H_1-receptor antagonist, terfenadine, in chronic severe asthma, 671
WOOD-BAKER R., TOWN G.I., BENNING B. & HOLGATE S.T. The reproducibility and effect of non-specific airway responsiveness on inhaled prostaglandin D_2 and leukotriene D_4 in asthmatic subjects, 119
WOOTTON R. *see* PECK R.W.
WOOTTON R. *see* ROLAN P.E.
WRIGHT J.D., HELSBY N.A. & WARD S.A. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides, 441
WRITER D.J. *see* FAIRLESS A.J.
WUTTGE D.M. *see* ZIEDEN B.
WYLD P.J. *see* NASSIM M.A.
WYNANT P. *see* BELPAIRE F.M.
WYNNE H. *see* KAMALI F.

XU B.Q. *see* AASMUNDSTAD T.A.

YATES R.A. *see* DONOVAN A.J.G.
YATES R.A. *see* HUSSEIN Z.
YEO W.W. *see* HAQ I.U.
YEO W.W. *see* KRASKIEWICZ M.
YEO W.W. *see* TODD G.P.
YEO W.W., HIGGINS K.S., FOSTER G., JACKSON P.R. & RAMSAY L.E. Effect of dose adjustment on enalapril-induced cough and the response to inhaled capsaicin, 271
YEW W.W. *see* WILLIAMSON I.J.
YOGENDRAN L. *see* GUNPUT M.D.
YORK A. *see* HOLFORD N.H.G.
YORK M. *see* ENTWISLE S.J.
YOSHIMOTO K., ECHIZEN H., CHIBA K., TANI M. & ISHIZAKI T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers—*N*-desiso-propylation is mediated mainly by CYP1A2, 421

ZAHLSON K. *see* KLEMSDAL T.O.
ZECH P.Y. *see* FAUVEL J.P.
ZIEDEN B., WUTTGE D.M., KARLBERG B.E. & OLSSON A.G. Effects of *in vitro* addition of

captopril on copper-induced low density lipoprotein oxidation, 201
ZIELENIUK I. *see* PATAT A.
ZIPFEL A. *see* ROSENZWEIG P.
ZOPPI A. *see* FOGARI R.
ZUPPI C. *see* SCATENA R.
ZUSSMAN B.D., DAVIE C.C., FOWLES S.E., KUMAR R., LANG U., WARGENAU M. & SOURGENS H. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism *in vivo*, 550P

SUBJECT INDEX

This index was compiled from the keywords

(P = Proceedings, S = Supplement)

ACE gene, 131
ACE inhibitor, 575, 545P, 688
ACTH, 389
AIDS, 587P
Absorption, 194
Absorption interactions, 449
Accidental falls, 227
Acetominophen, 330
Acetylator phenotype, 551P
Acute myocardial infarction, 704
Acyl glucuronide, 692
Adsorption, 330
Adverse drug reactions, 223, 265, 460
Adverse reactions, 289
Age, 35, 102P
Aged, 227
Alcohol, 584P
α_1-acid glycoprotein, 190
α_2-adrenoceptor antagonism, 243
α_2-adrenoceptor antagonist, 477
Alzheimer's disease, 566P
Amantadine, 81
Amikacin, 578P
Aminoglycosides, 578P, 597, 605
[4-amino-2-(4-methylpiperazine-l-yl)]-5-(2,3,5-trichlorophenyl) pyrimidine, 562P
Aminosalicylic acid, 456
Amlodipine, 45, 471, 578P, 641
Amoxycillin, 460
Analgesic effect, 182
Angina pectoris, 542P, 543P, 584P
Angiotensin, 51
Angiotensin II receptor antagonist, 579P
Angiotensin II receptor blockade, 541P
Angiotensin I, 497
Angiotensin II, 497
Angiotensin converting enzyme, 131
Angiotensin converting enzyme inhibitor, 125, 265
Antacid, 17S
Anti-rheumatic drug, 25S
Anti-sickling agent, 375
Antihistamines, 31, 671
Antimalarial, 441
Antitussive dextromethorphan, 261
Anxiety, 235
Anxiety paradigm, 571P
Apparent volume of distribution, 81
Appetite suppressants, 97P
Applied potential tomography, 585P
Arterial resistance, 45
Arthritis, 51S
Arylamine *N*-acetyltransferase, 85
Aspirin, 106P
Asthma 109, 119, 671
Atenolol, 471, 587P
Audit, 99P, 197
Azathioprine, 456

β-adrenoceptor blocker, 572P
β_1-adrenoceptor antagonist, 587P
β_1-adrenergic sensitivity, 633
β_2-adrenoceptor, 109
β_2-adrenoceptor agonist, 587P
β_2-adrenoceptor antagonist, 587P
β_3-adrenoceptor agonist, 581P, 582P
Beclamethasone, 709
Befloxatone, 565P, 574P
Benzodiazepine, 31
Bias, 485
Bile, 627
Bilirubin, 169
Bioavailability, 17S, 101P, 143
Blood flow, 92P
Blood pressure, 485, 541P, 580P
Brachial artery, 641
Bradykinin, 497, 545P
Bronchial responsiveness, 119
Bronchoconstriction, 587P
Bronchospasm, 265
Buccal, 449
Budesonide, 709
Busipone, 243

CCK, 235
CCK_B antagonists, 235
cDNA-expressed microsomes, 321
CNS depression, 548P
CYP inhibitors, 553P
CYP1A2, 321, 421, 433
CYP2C19, 297, 421, 433, 441, 511
CYP2D6, 417, 421, 433, 611
CYP2E1, 321
CYP3A4, 553P
Caffeine, 65, 558P
Calcium antagonists, 491
Capsaicin, 271
Capsaicin-induced cough, 545P
Captopril, 51, 497, 688
Carbamazepine, 554P
Carbamazepine hypersensitivity, 555P
Carbon monoxide, 665
Cardiovascular haemodynamics, 572P
Caucasians, 361
Celiprolol, 485
Chemoprophylaxis, 696
Chinese, 361, 551P
Chiral h.p.l.c., 558P
4-chlorophenylbiguanide, 29
Chlororoquine, 696
Chlorproguanil, 441
Cholesterol, 333, 544P
Cimetidine, 21S
Ciprofloxacin, 305
Cis-stilbene oxide, 554P
Citric acid, 261
Clearance, 39S
Clinical trial, 106P, 204
Clinical trial design, 313
Clinical trials, 211
Clinical trials, phase 1, 405
Clonazepam, 449
Clonidine, 477, 575P, 580P
Co-trimoxazole, 101P, 557P
Codeine, 182
Cognitive function, 31, 333
Cohort study, 265
Cold pain test, 549P, 565P
Colonic transport, 107P
Committee on Safety of Medicines, 223
Concentration/effect-analysis, 39
Continuous infusion, 549P
Continuous venovenous haemofiltration, 588P
Controlled release, 39
Coronary heart disease, 25
Cortisol, 389
Cough, 125, 265, 271, 545P
Cough reflex, 261
Coumarin, 71
Creatinine kinase, 135
Crossover effects, 106P
Cumulative dose-response curves, 574P
Cyclo-oxygenase, 543P
Cyclo-oxygenase inhibitors, 45
Cycloguanil, 297
Cyclosporin, 627
Cyclosporin A, 172, 337
Cystic fibrosis, 85
Cytochrome P450 isoforms, 71
Cytochrome P4501A2, 65
Cytochrome P4502D6, 77, 182, 556P
Cytochrome P450, 421

D0870, 562P
DU 29894, 7
Desipramine, 251, 550P, 586P
Detrusor hyperreflexia, 207
Developing countries, 1
Dexfenfluramine, 684
Diabetes, 576P
3,4,diaminopyridine, 102P
Dideoxyinosine, 527
Diet, 543P
Digoxin, 43S
Digoxin interaction, 491
Diltiazem, 277
Dipipanone, 549P, 565P
Diuretic resistance, 51
Diurnal variation, 543P
Divided attention, 548P
Dobutamine, 633
Dopamine, 92P
Dopamine D_4 receptor, 547P
Dosing, 605
Dothiepin, 397
Doxazosin, 369
Driving, 570P
Driving performance, 397
Drug adverse reaction, 621
Drug interaction, 51S
Drug interactions, 305

Drug metabolism, 85
Drug utilization, 1
Drugs, 343
Drugs utilization, 227

Editorial comment, 595
882C87, 141
Elderly, 465, 540P, 569P, 572P
Emesis, 97P
Enalapril, 131, 271, 541P, 545P
Enantiomers, 94P, 102P, 190, 536, 558P
Endothelin 1, 546P
Endothelin A receptors, 546P
Endothelin B receptors, 546P
Enoxacin, 194
Enzyme induction, 99P
Epilepsy, 567P
Epoxide hydrolase, 554P
Erythema, 63S
Erythrocyte sodium-lithium counter transport, 584P
Erythrocytes, 25
Essential drugs, 1
Ethanol, 548P, 570P
Ethinyloestradiol, 47S
Ethnic origin, 551P
Ethylmorphine, 77, 611
Excretion, 176
Exercise, 135, 582P, 677
Exercise tolerance, 277, 542P
Expired air, 665
Extended-release isosorbide 5-mononitrate, 704

FPL 67085, 98P
Falciparum malaria, 283
Fasting, 169
Fat, 585P
Feed-back controlled pump, 15
Felodipine, 94P, 573P
Fibrates, 25
Fibrinogen, 471
Flesinoxan, 7
Fluconazole, 567P
Fluoxetine, 397
Fluparoxan, 477
Flupenthixol, 570P
Flurbiprofen, 559P
Fluticasone, 709
Fluvoxamine, 151
Foetal serum, 190
Food, 175, 194, 561P
Food intake, 485
Forearm plethysmography, 540P
Formoterol, 109
Frusemide, 51
Frusemide pharmacokinetics, 692

GR122311X, 106P
GSTM1*0, 411
Gait analysis, 569P
Gamma-L-glutanyl-5-hydroxy-L-tryptophan, 327
Gamma scintigraphy, 381
Gastric emptying, 585P
Gastric pH, 15
Gastrin, 161
Gastrin levels, 511
Gemfibrozil, 25
Gender, 3S, 81
Genetic polymorphism, 131, 182
Genetics, 417
Gingival overgrowth, 99P, 100P, 567P, 568P
Glucocorticoids, 709
Glutamine, 588P
Glutathione-S-transferase μ genotype, 411, 555P
Glyceryl trinitrate, 576P
Graft rejection, 176
Grapefruit juice, 337
Guidelines, 217

HIV, 551P
HIV infection, 587P, 621
HIV reverse transcriptase, 551P
HIV screening, 212
HIV seropositivity, 463
HMG Co A reductase inhibitors, 544P
5-HT_1 receptor agonist, 95P
Haemodynamic response, 583P
Haemodynamics, 45, 347
Haemoglobin, 25
Hair analysis, 665
Halofantrine, 283, 519, 556P
Haloperidol, 7
Hawksley random zero sphymomanometer, 580P
Healthy subjects, 243
Healthy volunteer population, 463
Healthy volunteers, 35S, 43S, 59, 213, 571P, 633, 657
Heart failure, 51, 633
Heart rate, 577P, 582P
Hepatic function, 71
Hepatic metabolism, 421
Heterozygotic twins, 560P
Histamine, 671
Homozygotic twins, 560P
Hormonal profile, 541P
Human, 305, 347, 611
Human foetal placental circulation, 497
Human hypertension, 45
Human liver microsomes, 77
Hydrochlorothiazide, 471
4-hydroxypropranolol, 421
1-hydroxy tacrine, 103P, 556P
5-(4-hydroxyphenyl)-5-phenylhydantoin, 567P, 568P
5-hydroxytryptamine, 327, 576P
5-hydroxytryptophan, 327
Hypercholesterolaemia, 135
Hyperlipidaemia, 544P
Hypertension, 515, 575, 93P, 94P, 271, 465, 471, 572P, 578P, 641
Hypotension, 51S

Ibuprofen, 45
Ifosfamide, 452, 454
Imidapril, 93P
Imipramine, 433
Infusion, 15
In vitro, 321
Indomethacin, 497
Indonesians, 297
Inflow and voiding cystometry, 207
Inhalation challenge, 119
Inhibition of phenytoin metabolism, 100P
Inodilators, 485
Inter-observer, 104P
Interaction 21S, 31, 43S, 57S, 106P, 557P, 570P, 692, 700
Intra-observer, 104P
Intranasal, 449
Intravenous, 15
Intravenous administration, 182
Ipecacuanha-induced model, 97P
Ipsapirone, 243
Irbesartan, 579P
Isoniazid, 551P
Isoprenaline, 347, 485, 581P, 583P, 633
Isosorbide mononitrate, 542, 584P

Jordanian, 179

Kidney, 327
Kidney function, 71
Korotkoff sounds, 485

L-365,260, 234
L-NMMA, 92P, 546P
Lamotrigine, 549P, 565P
Latin square, 106P
Leukocyte, 85
Leukotriene D_4, 119
Levcromakalim, 207
Levodopa, 39
Levonorgestrel, 47S
Lexipafant, 546P, 561P
Light reflex, 251
Liposomes, 59P
Lisinopril, 471
Lithium carbonate, 25S
Liver cirrhosis, 445
Liver microsomes, 552P
Liver transplantation, 627
Liver volume, 101P
Long-term pH-metry, 161
Loperamide, 101P, 557P
Loratidine, 560P
Lorazepam, 31
Low density lipoprotein, 201
Luminol chemiluminescence, 688

MAO-A inhibitor, 565P, 574P
MEGX, 71
Malaria, 519, 696
Malaria chemoprophylactic prodrug, 297
Man, 503
Mannitol, 381
Maternal serum, 190
Medical education, 1
Medical practitioners, 223
Membrane cholesterol/phospholipid, 584P
Memory, 31, 565P
Mephenytoin, 433, 511
Mephenytoin hydroxylase, 441
6-mercaptopurine, 456
Meribendan, 485
Metabolic probe, 65
Metabolism, 115, 176, 611, 621
Metabolites, 536
Methadone, 564P
Methoxamine, 575P, 586P

Methylprednisolone-hemisuccinate, 176
Microemulsion, 627
Microsomes, 151
Midazolam, 567P
Migraine, 96P, 572P
Milk, 194
Mizolastine, 31, 570P
Money, 343
Morphine, 182, 549P, 611, 704
Multifactorial, 125
Multiple dose, 696
Muscle biopsy, 135
Mydriasis, 575P
Myocardial ischaemia, 531
Myoglobin, 135
Myopathy, 135

N-desisopropylpropranolol, 421
N-oxidation, 179
Naftopidil, 369
Naloxone, 257
Natriuresis, 92P
Nausea, 97P
Neuro-endocrine, 7
Neuroleptic, 417
Neuroleptics, 503
New drugs, 99P
N^G-monomethyl-L-arginine, 92P
Nicardipine, 540P
Nicotine, 665, 677
Nicotine patch, 100P
Nitric oxide, 92P
Nitroglycerin patch, 542P
Nocebo, 204
Non-compartmental analysis, 562P
Non-cumulative dose-response curves, 574P
Non-invasive, 347, 485
Non-invasive assessment, 583P
Noradrenaline, 574P, 586P

Obesity, 684
Obituary, 341
Octylonium bromide, 107P
Omeprazole, 15, 511
Once daily sustained-release formulation, 277
Once-daily, 605
Open heart surgery, 578P
Ophthalmic solution, 257
Opiate addiction, 257
Opiate addicts, 564P
Opioid agonist, 338, 339
Oral contraceptive, 47S
Oral dose, 611
Osteoarthritis, 3S
Overdose, 680
Oxidation, 179, 201
Oxygen toxicity, 25

P2t-purinoceptor antagonist, 98P
PCA, 182
PR interval, 577P
PTCA contractility, 531
Pancreatoduodenectomy, 330
Pantoprazole, 700
Paracetamol, 330
para-amino benzoic acid, 85
Parasite chemosensitivity, 283
Parathyroid hormone, 161
Parkinson's disease, 39
Parkinsonism, 569P
Patient controlled analgesia, 549P
Patient knowledge, 197
Patient recruitment, 211
Penciclovir, 553P
Pentagastrin, 235
Pentamidine, 289, 587P
Performance, 567P
Perindopril, 361
Perindoprilat, 361
Peroxisome proliferators, 25
Personality, 204
Personality assessment, 405
Pharmacodynamics, 29S, 375, 477, 700
Pharmacokinetics, 35, 11S, 17S, 21S, 35S, 39S, 43S, 47S, 59, 141, 161, 172, 187, 283, 289, 305, 361, 375, 445, 449, 454, 503, 511, 519, 527, 540P, 553P, 557P, 558P, 560P, 561P, 562P, 564P, 572P, 573P, 611, 621, 677, 680, 684, 700
Phase I studies, 657
Pheniramine, 560P
Phenotype, 511
Phenylephrine, 347
Phenytoin, 99P, 100P, 567P
Phototoxicity, 63S
Physiology, 227
Physostigmine, 59
Piroximone, 187
Placebo, 204, 657
Plasma concentrations, 15
Plasma determination, 102P
Plasma protein binding, 29S, 39S
Plasmodium falciparum, 519
Platelet activating factor, 546P
Platelet aggregation, 98P, 369, 543P, 546P
Polymorphism, 77
Population analysis, 562P
Population pharmacodynamics, 313
Post-operative pain, 549P
Postoperative shivering, 580P
Posture, 227
Pravastatin, 135, 333
Prescribing, 97P, 99P, 107P, 465
Prescribing pattern, 1
Primary care, 107P
Probenecid, 692
Professor Paul Turner, 341
Proguanil, 297, 441
Prolactin, 503
Propranolol, 190, 540P, 587P
Propranolol enantiomers, 421
Proprioception, 227
Prostacyclin, 45
Prostaglandin D_2, 119
Prostaglandins, 92P
Prostanoids, 543P
Protein binding, 3S, 11S, 103P, 190, 211, 536, 556P
Psychology, 405
Psychometric performance, 397
Psychomotor performance, 31, 558P, 565P, 570P
Psychopharmacology, 31
Pupil, 251, 257
Pupillometry, 257
Pylorus preserving, 330
1,(2-pyrimidinyl)-piperazine, 243

QT dispersion, 104P, 105P
QT interval, 94P, 104P, 105P, 577P
Quality of life, 217

R 56865, 531
R-ifosfamide, 454
Ranitidine, 106P
Reaction time, 227
Reboxetine, 251
Refractoriness, 503
Reliability of self-report, 665
Remoxipride, 3
Renal clearance, 25S, 81, 692
Renal haemodynamics, 572P
Renal insufficiency, 161, 187
Renal transplant, 337
Reproducibility, 125
Respiration, 105P
Rheumatoid arthritis, 3S, 131, 172
Rigidity, 563P
Ro 40-5967, 491
Romazarit, 313
Roxatidine, 161

S-ifosfamide, 454
S-mephenytoin 4'-hydroxylase (CYP2CMP,CYP2C19), 297
SI units, 589, 595
Salbutamol, 109
Salivary nitrite, 460
Salmeterol, 109, 587P
Salt depletion, 579P
Schizophrenia, 417, 547P, 570P
Serotonin selective reuptake inhibitors, 151, 550P
Sertraline, 550P
Serum protein binding, 519
Sex differences, 347
Short bowel syndrome, 330
Sickle cell disease, 375
Side effects, 25, 397
Simavastatin, 135, 333
619C89, 562P
Skin reaction, 63S
Sleep, 397, 558P
Sleeping sickness, 289
Small intestinal transit, 381
Smoking, 81
Smoking behaviour, 665
Society, 343
Sodium, 51
Sodium acid pyrophosphate, 381
Sodium nitroprusside, 347
Sparteine, 433
Spasmolytic, 107P
Spinal cord lesion patients, 207
Stable angina pectoris, 277
Stroke, 562P
Subsensitivity, 109
Sucrose, 381
Sulphamethoxazole, 85, 621
Sulphamethoxazole hydroxylamine, 621
Sulphasalazine, 456
Sulpiride, 7
Sumatriptan, 95P, 96P, 389, 572P
Superoxide, 688

Survey, 223
Systolic time intervals, 95P

Tacrine, 103P, 411
Tacrine hydrochloride, 566P
Temperature, 7
Tenidap, 3S, 11S, 43S
Tenidap sodium, 17S, 21S, 25S, 29S, 39S, 47S, 51S, 57S, 63S
Tenidap-phenytoin interaction, 35S
Teniloxazine, 445
Terfenadine, 671
Terodiline, 94P, 558P
Tertatolol, 572P
Testosterone, 553P
Theophylline, 151, 305
Theophylline hydroxylation, 552P
Theophylline metabolism, 321
Theophylline *N*-demethylation, 552P
Therapeutic monitoring, 566P
Thiazide diuretic, 51S
Thiol, 688
Thiopurine methyltransferase, 456
Thrombolysis, 95P
Thromboxane, 45
Thromboxane A_2 receptor, 95P
Tolbutamide, 39S
Tolerability, 578P
Tolerance, 3, 109
Tourette's syndrome, 100P
Tramadol hydrochloride, 338, 339
Transaminitis, 411
Transdermal, 100P, 677
Transdermal nitroglycerin, 584P
Transdermal system, 59
Transthoracic electrical bioimpedance, 583P
Treatment, 217
Triazole antifungal agent, 562P
Trigger factors, 125
Trimethylamine, 179
Trypanosoma gambiense, 289
Tyramine, 575P
Tyramine pressor test, 574P

UP 269-6, 541P
Ulcer healing drugs, 197

Valproic acid, 560P
Vapiprost, 95P
Variability, 15, 577P
Varicella zoster virus, 141
Velnacrine, 556P
Venodilatation, 543P
Venous compliance, 576P
Verapamil, 190, 536, 680
Voluntary workers, 405
Volunteers, 7

Warfarin, 29S, 95P, 101P, 211, 700

Xamoterol, 107P
Xanthine oxidase, 688

ZD2079, 581P, 582P
Zalcitabine, 551P
Zidovudine, 527